Compare Inovio Pharmaceuticals Inc (INO) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Consumer Staples Select Sector SPDR Fund trades at $84.08. The key difference: Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | XLP | |
|---|---|---|
Market Cap | $89.27M | — |
Sector | Health | — |
52-Week High | $2.87 | $90.00 |
52-Week Low | $1.05 | $75.61 |
Enterprise Value | $60.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
XLP trades at $84.86, down 0.39% on the day, with a bullish technical signal supported by moving averages. The ETF maintains a 2.6% dividend yield and shows strength in defensive positioning amid market volatility. Analyst consensus is unanimously positive with 2 buy ratings and no hold or sell recommendations.
The consumer staples ETF offers defensive exposure during economic uncertainty, with technical indicators supporting near-term upside potential. Key risks include sector concentration and competition from broader alternatives. Current levels near pivot point resistance at $86 represent the immediate technical challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
